{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:42:14Z","timestamp":1792208534079,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Locally advanced esophageal adenocarcinoma has a poor prognosis and limited treatment options when surgery is not possible or desired. Although definitive chemoradiotherapy (dCRT) is currently administered as a curatively intended treatment, limited data exist regarding its efficacy for patients with adenocarcinoma of the esophagus, necessitating further evaluation of survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with a diagnosis of adenocarcinoma of the esophagus or esophago-gastric junction who had undergone dCRT (defined as a radiation dose of &gt;\u200941.4 Gy and \u2264\u200950.4 Gy, respectively) were identified from the nationwide Netherlands Cancer Registry (2015\u20132022). Overall survival (OS) was analyzed, and multivariable Cox regression analysis was performed to evaluate prognostic factors. Progression-free survival (PFS) was estimated for the subgroup of patients with detailed follow-up data from 2015 to 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study analyzed 926 patients, including 263 patients with data on recurrence patterns. Of these patients, 77% had a diagnosis of stage III\/IVa disease, and 72% had a WHO performance status of 0 to 1. The 90-day mortality rate was 7.1%. The median OS was 19.6 months (95% confidence interval [CI], 18.6\u201321.2 months), and the 3-year OS was 28%. The median PFS was 12.1 months (95% CI, 9.7\u201314.0 months). Clinical T3\u2013T4 category, cN+ category, WHO performance status, and tumor length were linked to worse survival, although the multivariable model had limited discriminatory power.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Real-world OS and PFS for patients with adenocarcinoma of the esophagus or esophago-gastric junction who received dCRT were poor, and 90-day mortality was substantial. These outcomes highlight the need for optimal patient selection, well-informed shared decision-making, and the development of improved treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20428-3","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:36:00Z","timestamp":1787596560000},"page":"10375-10383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Definitive Chemoradiotherapy for Adenocarcinoma of the Esophagus or Esophago-Gastric Junction: A Dutch Population-Based Cohort Study"],"prefix":"10.1245","volume":"33","author":[{"given":"S. S. G.","family":"Gangaram Panday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Khoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. W. M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nuyttens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S. N.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H. A.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. P. L.","family":"Wijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"20428_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin."},{"key":"20428_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392:323\u201335.","journal-title":"N Engl J Med."},{"key":"20428_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","volume":"8","author":"JV Reynolds","year":"2023","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B, Lowery MA, Baeksgaard L, Crosby T, et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8:1015\u201327.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"20428_CR4","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384.","journal-title":"N Engl J Med."},{"key":"20428_CR5","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191\u2013203.","journal-title":"N Engl J Med."},{"key":"20428_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393:217\u201330.","journal-title":"N Engl J Med."},{"key":"20428_CR7","doi-asserted-by":"crossref","unstructured":"van der Zijden CJ, Bouwman A, Mostert B, Nuyttens J, van der Sluis PC, Spaander MCW, et al. Overall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study. Dis Esophagus. 2024;37.","DOI":"10.1093\/dote\/doae047"},{"key":"20428_CR8","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1200\/JCO.20.00866","volume":"38","author":"AS Manish","year":"2020","unstructured":"Manish AS, Erin BK, Daniel VC, Dana CD, Karyn AG, Narinder KM, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020;38:2677\u201394.","journal-title":"J Clin Oncol."},{"key":"20428_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/annonc\/mdt589","volume":"25","author":"J Honing","year":"2014","unstructured":"Honing J, Smit JK, Muijs CT, Burgerhof JGM, de Groot JW, Paardekooper G, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25:638\u201343.","journal-title":"Ann Oncol."},{"key":"20428_CR10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94\u201305) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167\u201374.","journal-title":"J Clin Oncol."},{"key":"20428_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijrobp.2023.05.025","volume":"117","author":"M Pape","year":"2023","unstructured":"Pape M, Veen LM, Smit TM, Kuijper SC, Vissers PAJ, Geijsen ED, et al. Late toxicity and health-related quality of life following definitive chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2023;117:31\u201344.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"20428_CR12","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1200\/JCO.20.03697","volume":"39","author":"M Hulshof","year":"2021","unstructured":"Hulshof M, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study). J Clin Oncol. 2021;39:2816\u201324.","journal-title":"J Clin Oncol."},{"key":"20428_CR13","doi-asserted-by":"crossref","unstructured":"Jensen GL, Hammonds KP, Haque W. Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities. Dis Esophagus. 2023;36.","DOI":"10.1093\/dote\/doac050"},{"key":"20428_CR14","doi-asserted-by":"publisher","first-page":"e2440568","DOI":"10.1001\/jamanetworkopen.2024.40568","volume":"7","author":"WJ Jeon","year":"2024","unstructured":"Jeon WJ, Park D, Al-Manaseer F, Chen YJ, Kim JY, Liu B, et al. Survival and treatment patterns in stage II to III esophageal cancer. JAMA Netw Open. 2024;7:e2440568.","journal-title":"JAMA Netw Open."},{"key":"20428_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1080\/0284186X.2018.1450521","volume":"57","author":"M Ko\u00ebter","year":"2018","unstructured":"Ko\u00ebter M, van Putten M, Verhoeven RHA, Lemmens V, Nieuwenhuijzen GAP. Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival. Acta Oncol. 2018;57:1192\u2013200.","journal-title":"Acta Oncol."},{"key":"20428_CR16","doi-asserted-by":"crossref","unstructured":"Muneeb K, Shree R, Maha Z, Muhammad Ramish S, Qasim M, Azka A, et al. Comparison of intensity-modulated radiotherapy and 3D conformal radiotherapy in the treatment of esophageal carcinoma: a systematic review and meta-analysis. J Clin Oncol. 2025;43(16_Suppl):e16001-e.","DOI":"10.1200\/JCO.2025.43.16_suppl.e16001"},{"key":"20428_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.21037\/acs.2017.03.14","volume":"6","author":"TW Rice","year":"2017","unstructured":"Rice TW, Patil DT, Blackstone EH. 8th-Edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6:119\u201330.","journal-title":"Ann Cardiothorac Surg."},{"key":"20428_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Software. 2011;45:1\u201367.","journal-title":"J Stat Software."},{"key":"20428_CR19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ijrobp.2022.11.006","volume":"115","author":"J You","year":"2023","unstructured":"You J, Zhu S, Li J, Li J, Shen J, Zhao Y, et al. High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial. Int J Radiat Oncol Biol Phys. 2023;115:1129\u201337.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"20428_CR20","doi-asserted-by":"crossref","unstructured":"Ronan Joseph K, Jaffer AA, Jaroslaw K, Thomas Z, Eric Van C, Guillaume P, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiotherapy (CRT): first results of overall survival (OS) from CheckMate 577. J Clin Oncol. 2025;43(16 Suppl):4000\u2013.","DOI":"10.1200\/JCO.2025.43.16_suppl.4000"},{"key":"20428_CR21","doi-asserted-by":"crossref","unstructured":"van Laarhoven H, Verhoeven R, van Berge Henegouwen M, Mohammad NH, van Hillegersberg R, Slingerland M, et al. Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands. eClinicalMedicine. 2025;80:103067.","DOI":"10.1016\/j.eclinm.2024.103067"},{"key":"20428_CR22","doi-asserted-by":"crossref","unstructured":"Jiang W, Verma V, Haque W, Moreno AC, Koshy M, Butler EB, Teh BS. Post-treatment mortality after definitive chemoradiotherapy versus resection for esophageal cancer. Dis Esophagus. 2020;33.","DOI":"10.1093\/dote\/doz073"},{"key":"20428_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/SLA.0000000000000482","volume":"260","author":"AK Talsma","year":"2014","unstructured":"Talsma AK, Lingsma HF, Steyerberg EW, Wijnhoven BP, Van Lanschot JJ. The 30-day versus in-hospital and 90-day mortality after esophagectomy as indicators for quality of care. Ann Surg. 2014;260:267\u201373.","journal-title":"Ann Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20428-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20428-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20428-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:23:36Z","timestamp":1792207416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20428-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["20428"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20428-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}